title: Variability in aggregometry response before and after initiation of clopidogrel therapy.
abstract: BACKGROUND
  Evaluation of clopidogrel therapy by in vitro methods has limitations which may be of clinical importance. We wanted to explore the variability in aggregometry response in aspirin sensitive patients before and after initiation of clopidogrel therapy.
  
  
  METHODS
  ADP 9.37 microM, AA 1.2mM and TRAP 25 mM stimulated light transmissions aggregometry (LTA) were performed twice before (Exams 1 and 2; 3 weeks apart)-and within one year after-initiation of clopidogrel therapy (Exam 3) in 79 patients treated with PCI. Repeated ADP aggregometry was also performed in 16 healthy volunteers in order to estimate LTA measurement error.
  
  
  RESULTS
  Inter-individual differences in ADP aggregation e.g. at Exam 1 were substantial (range 17-77%, SD 15.8%). Intra-individual changes between Exams 1 and 2 were significant (-27 to +36%, SD 14.6%, p<0.05). Inter-individual differences at Exam 3 (on clopidogrel treatment) were larger than expected from Exams 1 and 2 (p<0.01). AA aggregation was the same before and during clopidogrel treatment. In controls, inter-individual differences were smaller at ADP 10 than at ADP 5 microM.
  
  
  CONCLUSIONS
  Inter-individual differences in ADP aggregation were significant both before and during clopidogrel therapy, and there were significant intra-individual variations over time. Therefore, prediction of aggregometry response before or during clopidogrel therapy based on single tests may be unreliable. Inter-individual differences in healthy controls are smaller at high concentrations of ADP, and comparisons of aggregometry response should be performed with caution unless ADP concentrations are standardized.
authors.affiliation: Department of Medicine, Blefjell Hospital HF, Norway.
authors.forename: Øystein
authors.initials: Ø
authors.lastname: Meen
authors.forename: Frank
authors.initials: F
authors.lastname: Brosstad
authors.forename: Stine
authors.initials: S
authors.lastname: Bjørnsen
authors.forename: Turid Margrethe
authors.initials: TM
authors.lastname: Pedersen
authors.forename: Gunnar
authors.initials: G
authors.lastname: Erikssen
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D016022:Case-Control Studies; D000077144:Clopidogrel; D003710:Demography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010979:Platelet Function Tests / Q000379:methods*; D015203:Reproducibility of Results; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; C086309:thrombin receptor peptide SFLLRNP; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin